In the cancer development, CFAP65 has been demonstrated to participate in mitochondrial retrograde signaling pathway mediated by TFAM depletion, which has been verified to reduce cell proliferation in esophageal, arsenical skin, and prostate cancers, thereby affecting tumor cell proliferation and differentiation [10]. Here, CFAP65 is linked to cancer.